Markets

Insider Trading

Hedge Funds

Retirement

Opinion

David Einhorn Stock Portfolio: Top 10 Stock Picks

David Einhorn of Greenlight Capital manages a 13F portfolio that was worth more than $2.8 billion at the end of the fourth quarter of 2025. Einhorn is a long-short value investor renowned for his forensic approach to financial analysis. Since launching his firm in 1996, he has specialized in identifying deep-value opportunities while simultaneously executing high-profile short positions against companies with questionable accounting or flawed business models. Einhorn gained legendary status for his prescient 2008 short call on Lehman Brothers. In his latest investor letter, Einhorn has signaled a pivot toward extreme caution, prioritizing “capital preservation” despite a surging stock market. While the S&P 500 has staged a rebound to erase losses since the onset of the US-Iran conflict, Einhorn warned that market participants are dangerously complacent regarding geopolitical and macroeconomic risks.

READ MORE: 15 Best Stocks to Buy According to Billionaire Ray Dalio.

In the letter, Einhorn criticized the current investment climate, suggesting that even those who claim to be wary are not truly de-risking. He observed that investors are operating with a “Sammy Hagar inspired mentality: one foot on the brake and one on the gas.” According to Einhorn, this behavior stems from a fear of being left behind, as “nobody wants to miss the V- or even the checkmark-shaped recovery.” This optimism persists even though recent diplomatic efforts have faltered. While the market rallied on the hope of a breakthrough, Einhorn remains skeptical of the current valuations, noting that there is “so little downside priced in” to current equity levels. Despite his defensive posture, Greenlight Capital outperformed the broader market in the first quarter of 2026.

READ MORE: 10 Best Stocks to Buy According to Billionaire Paul Tudor Jones.

Our Methodology

To compile our list of the best stocks to buy according to billionaire David Einhorn, we reviewed the latest 13F filings of Greenlight Capital. Next, we focused on the top 10 stocks in his portfolio. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q4 2025 database of 1041 elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

David Einhorn Stock Portfolio: Top Stock Picks

10. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Greenlight Capital’s Stake: $95 Million 

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has featured in the 13F portfolio of Greenlight Capital since the fourth quarter of 2023. Back then, this position comprised 268,000 shares. In the coming quarters, the fund steadily loaded up on the stock, increasing the stake by 21%, 44%, and 21%. A massive buying activity was registered in the second quarter of 2025 when the fund increased this holding by more than 550%. Filings for the fourth quarter of 2025 show that the fund owns just over 3 million shares in the pharma firm, down close to 20% compared to filings for the third quarter of 2025.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been on the radar of elite hedge funds as the firm makes a strategic shift toward innovative, high-margin brand drugs. The best example of this is AUSTEDO, a treatment for tardive dyskinesia whose sales grew significantly in 2025 and are projected to hit $2.5 billion by 2027. Another catalyst for the shares is that in the fourth quarter of 2025, for the first time, Teva’s innovative brands – AUSTEDO, AJOVY, and UZEDY – collectively delivered over $1 billion in a single quarter. Pipeline drugs look promising as well. Teva is developing a potential blockbuster for inflammatory bowel disease. Recent data positions it as a best-in-class therapy. Institutional interest peaked after a $400 million funding agreement with Blackstone to accelerate its development.

9. Kyndryl Holdings, Inc. (NYSE:KD)

Greenlight Capital’s Stake: $101 Million

Kyndryl Holdings, Inc. (NYSE:KD) has constantly featured in the 13F portfolio of Greenlight Capital since the fourth quarter of 2021. Back then, this position comprised 922,000 shares. The fund steadily built up this stake. By the fourth quarter of 2024, this holding had reached over 9 million shares. Thereafter, the fund started trimming the position, reducing it by 5% and 47% in the next two quarters. Filings for the fourth quarter of 2025 show that the fund owned 3.8 million shares in the company, down a little over 12% compared to filings for the previous quarter.

Kyndryl Holdings, Inc. (NYSE:KD) is attracting interest from elite investors who are betting on the ability of the firm to shed low-margin legacy contracts inherited from its IBM spinoff. Since becoming independent, Kyndryl has been replacing no-profit legacy deals with high-margin consulting work. This mix shift has allowed profits to grow even as overall revenue stays relatively flat. Institutions also view Kyndryl as an affordable AI play. Unlike hardware-heavy tech firms, Kyndryl’s value lies in its Kyndryl Bridge platform and Kyndryl Consult arm. Earlier this month, the company launched an AI-native platform designed for autonomous IT workflows. The firm has signed strategic partnerships with Google Cloud, Microsoft Azure, and AWS to modernize mainframes and move legacy systems to the cloud.

8. Centene Corporation (NYSE:CNC)

Greenlight Capital’s Stake: $109 Million 

Centene Corporation (NYSE:CNC) first appeared in the 13F portfolio of Greenlight Capital in the first quarter of 2020. This holding comprised 204,000 shares and was sold off within the next few months. A new position was then opened in the fourth quarter of 2024 that consisted of more than 870,000 shares. After trimming this stake in the first quarter of 2025, David Einhorn has added to it in each of the last three quarters. Filings for the fourth quarter of 2025 show that the fund owned more than 2.6 million shares in the company, up close to 70% compared to filings for the third quarter of 2025.

Centene Corporation (NYSE:CNC) stock took a beating in 2025 and hedge funds view this as a buying opportunity given the earnings potential of the firm. For example, Centene has guided for 40% growth in adjusted EPS for 2026, targeting over $3 per share. Institutional investors expect a coiled spring effect where Medicaid and ACA Marketplace rates—which lagged during the inflation of 2025—will realign with cost trends in 2026, restoring historical profit margins. Hedge funds also favor management’s value-over-volume approach. CEO Sarah London has aggressively moved to divest non-core assets to simplify the business. The recent deal to sell off the remaining Magellan Health businesses is seen as a major step in cleaning up the balance sheet and focusing on the core government-sponsored healthcare segments.

7. Capri Holdings Limited (NYSE:CPRI)

Greenlight Capital’s Stake: $116 Million    

Capri Holdings Limited (NYSE:CPRI) has been a constant feature in the 13F portfolio of Greenlight Capital since the first quarter of 2021, barring a few exceptions in late 2023 and early 2024. Back then, this position comprised just under 200,000 shares. The fund steadily added to this position and grew it to more than 1.6 million shares by the second quarter of 2023 before selling off the position completely. A new stake in the firm was purchased in the second quarter of 2024. This consisted of 684,000 shares. The fund has added to this in four of the next six quarters. Filings for the fourth quarter of 2025 show that the fund owned 4.7 million shares in the company, up 77% compared to filings for the previous quarter.

A major catalyst for institutional interest in Capri Holdings Limited (NYSE:CPRI) stock in recent months has been the completion of the Versace sale in December 2025. The proceeds from the Versace sale allowed Capri to drastically reduce its net debt, estimated at $1.5 billion post-sale. Hedge funds favor this leaner profile, which gives the company more flexibility to weather the current luxury slowdown. Management is now fully focused on a brand health transformation for its remaining core brands. Jimmy Choo, in particular, has shown resilience with 5% sales growth in early 2026, driven by strong full-price sell-through.

6. PG&E Corporation (NYSE:PCG)

Greenlight Capital’s Stake: $125 Million

PG&E Corporation (NYSE:PCG) is a relatively recent addition to the 13F portfolio of Greenlight Capital. The fund first disclosed a stake in the company in the third quarter of 2025. This position comprised close to 6.4 million shares. Filings for the fourth quarter of 2025 show that the fund owned 7.8 million shares in the firm, up more than 21% compared to filings for the previous quarter. The firm engages in the sale and delivery of electricity and natural gas to customers in northern and central California, the United States. It generates electricity using nuclear, hydroelectric, fossil fuel-fired, fuel cells, and photovoltaic sources.

Elite investors like PG&E Corporation (NYSE:PCG) stock as the firm reported solid 2025 results with EPS of $1.50, up from $1.36 in 2024. For 2026, management recently tightened guidance to $1.64–$1.66, implying a 10% year-over-year growth rate—well above the utility sector average. The company is also executing a $73 billion capital investment plan for 2026–2030. Institutional analysts have argued that this plan supports sustained 9% annual earnings growth through 2028. A new 2026 theme for utility investors is the surge in power demand from AI data centers. PG&E’s service territory in Northern California, including Silicon Valley, is the epicenter of the AI boom.

While we acknowledge the potential of PCG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PCG and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see David Einhorn Stock Portfolio: Top 5 Stocks Picks.

READ NEXT: D. E. Shaw Stock Portfolio: Top 10 Stocks to Buy and 10 Best Stocks to Buy According to Billionaire Rob Citrone.

Disclosure: None. Follow Insider Monkey on Google News.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.